Progressive Muscular Dystrophy in Alpha-sarcoglycan-deficient Mice
Overview
Authors
Affiliations
Limb-girdle muscular dystrophy type 2D (LGMD 2D) is an autosomal recessive disorder caused by mutations in the alpha-sarcoglycan gene. To determine how alpha-sarcoglycan deficiency leads to muscle fiber degeneration, we generated and analyzed alpha-sarcoglycan- deficient mice. Sgca-null mice developed progressive muscular dystrophy and, in contrast to other animal models for muscular dystrophy, showed ongoing muscle necrosis with age, a hallmark of the human disease. Sgca-null mice also revealed loss of sarcolemmal integrity, elevated serum levels of muscle enzymes, increased muscle masses, and changes in the generation of absolute force. Molecular analysis of Sgca-null mice demonstrated that the absence of alpha-sarcoglycan resulted in the complete loss of the sarcoglycan complex, sarcospan, and a disruption of alpha-dystroglycan association with membranes. In contrast, no change in the expression of epsilon-sarcoglycan (alpha-sarcoglycan homologue) was observed. Recombinant alpha-sarcoglycan adenovirus injection into Sgca-deficient muscles restored the sarcoglycan complex and sarcospan to the membrane. We propose that the sarcoglycan-sarcospan complex is requisite for stable association of alpha-dystroglycan with the sarcolemma. The Sgca-deficient mice will be a valuable model for elucidating the pathogenesis of sarcoglycan deficient limb-girdle muscular dystrophies and for the development of therapeutic strategies for this disease.
Native DGC structure rationalizes muscular dystrophy-causing mutations.
Liu S, Su T, Xia X, Zhou Z Nature. 2024; 637(8048):1261-1271.
PMID: 39663457 DOI: 10.1038/s41586-024-08324-w.
An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species.
Vu Hong A, Suel L, Petat E, Dubois A, Le Brun P, Guerchet N Nat Commun. 2024; 15(1):7965.
PMID: 39261465 PMC: 11390886. DOI: 10.1038/s41467-024-52002-4.
Mokhonova E, Malik R, Mamsa H, Walker J, Gibbs E, Crosbie R Int J Mol Sci. 2024; 25(11).
PMID: 38892308 PMC: 11173052. DOI: 10.3390/ijms25116121.
Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy.
Sun C, Serra C, Kalicharan B, Harding J, Rao M Cells. 2024; 13(7.
PMID: 38607035 PMC: 11011706. DOI: 10.3390/cells13070596.
Egawa T, Ogawa T, Yokokawa T, Kido K, Iyama R, Zhao H J Cachexia Sarcopenia Muscle. 2024; 15(3):883-896.
PMID: 38575520 PMC: 11154761. DOI: 10.1002/jcsm.13444.